lidocaine has been researched along with imiquimod in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Bai, J; Bao, L; Cai, X; Jiang, B; Li, Q; Li, X; Lou, F; Song, N; Sun, L; Sun, Y; Tang, S; Wang, B; Wang, H; Wang, Z; Wu, Y; Yin, Q; Yu, B; Zhou, H | 1 |
2 other study(ies) available for lidocaine and imiquimod
Article | Year |
---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Lidocaine Ameliorates Psoriasis by Obstructing Pathogenic CGRP Signaling‒Mediated Sensory Neuron‒Dendritic Cell Communication.
Topics: Animals; Calcitonin Gene-Related Peptide; Cell Communication; Dendritic Cells; Imiquimod; Interleukin-23; Lidocaine; Pilot Projects; Psoriasis; Rats; Sensory Receptor Cells | 2022 |